Li Z, Lin L, Wu H, et al. Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the Global Burden of Disease Study and implications for prevention. Front Public Health. 2021;9:559751. https://doi.org/10.3389/fpubh.2021.559751.

Article  PubMed  PubMed Central  Google Scholar 

Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62(1):118–33. https://doi.org/10.1016/S0034-7094(12)70110-1.

Article  CAS  PubMed  Google Scholar 

Brock L. Dexmedetomidine in adult patients in cardiac surgery critical care: an evidence-based review. AACN Adv Crit Care. 2019;30(3):259–68. https://doi.org/10.4037/aacnacc2019888.

Article  PubMed  Google Scholar 

Vandemoortele O, Hannivoort LN, Vanhoorebeeck F, Struys M, Vereecke HEM. General purpose pharmacokinetic-pharmacodynamic models for target-controlled infusion of anaesthetic drugs: a narrative review. J Clin Med. 2022;11(9). https://doi.org/10.3390/jcm11092487.

Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913. https://doi.org/10.1007/s40262-017-0507-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Romagnoli S, Amigoni A, Blangetti I et al. Light sedation with dexmedetomidine: a practical approach for the intensivist in different ICU patients. Minerva Anestesiol. 2018;84(6):731-46. https://doi.org/10.23736/S0375-9393.18.12350-9.

Lin YY, He B, Chen J, Wang ZN. Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? a meta-analysis. Crit Care. 2012;16(5):R169-R. https://doi.org/10.1186/cc11646.

Shokri H, Ali I. A randomized control trial comparing prophylactic dexmedetomidine versus clonidine on rates and duration of delirium in older adult patients undergoing coronary artery bypass grafting. J Clin Anesth. 2020;61:109622-. https://doi.org/10.1016/j.jclinane.2019.09.016.

Zi J, Fan Yo, Dong CH et al. Anxiety administrated by dexmedetomidine to prevent new-onset of postoperative atrial fibrillation in patients undergoing off-Pump coronary artery bypass graft. Int Heart J. 2020:https://doi.org/10.1536/ihj.19-132. https://doi.org/10.1536/ihj.19-132.

Piao GY, Wu JR. Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials. Arch Med Sci. 2014;10(1):19–24. https://doi.org/10.5114/aoms.2014.40730.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Habibi V, Kiabi FH, Sharifi H. The effect of dexmedetomidine on the acute pain after cardiothoracic surgeries: a systematic review. Braz J Cardiovasc Surg. 2018;33(4):404-17. https://doi.org/10.21470/1678-9741-2017-0253.

Penttilä J, Helminen A, Anttila M, Hinkka S, Scheinin H. Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Can J Physiol Pharmacol. 2004;82(5):359–62. https://doi.org/10.1139/y04-028.

Article  PubMed  Google Scholar 

Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382-94. 10.1097 / 00000542-200008000-00016.

Kang D, Lim C, Shim DJ, et al. The correlation of heart rate between natural sleep and dexmedetomidine sedation. Korean J Anesthesiol. 2019;72(2):164–8. https://doi.org/10.4097/kja.d.18.00208.

Article  CAS  PubMed  Google Scholar 

Yu GF, Jin SY, Chen JH, Yao WF, Song XR. The effects of novel α(2)-adrenoreceptor agonist dexmedetomidine on shivering in patients underwent caesarean section. Biosci Rep. 2019;39(2):BSR20181847. 10.1042/BSR20181847.

Geng ZY, Liu YF, Wang SS, Wang DX. Intra-operative dexmedetomidine reduces early postoperative nausea but not vomiting in adult patients after gynaecological laparoscopic surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016;33(10):761–6. https://doi.org/10.1097/EJA.0000000000000491.

Article  CAS  PubMed  Google Scholar 

Mahboobi SK. Dexmedetomidine and renal protection after cardiac surgery. J Clin Anesth. 2017;40:121–2. https://doi.org/10.1016/j.jclinane.2017.05.002.

Article  PubMed  Google Scholar 

Lin N, Vutskits L, Bebawy JF, Gelb AW. Perspectives on dexmedetomidine use for neurosurgical patients. J Neurosurg Anesthesiol. 2019;31(4):366–77. https://doi.org/10.1097/ANA.0000000000000554.

Article  PubMed  Google Scholar 

Wong A, Smithburger PL, Kane-Gill SL. Review of adjunctive dexmedetomidine in the management of severe acute alcohol withdrawal syndrome. Am J Drug Alcohol Abuse. 2015;41(5):382–91. https://doi.org/10.3109/00952990.2015.1058390.

Article  PubMed  Google Scholar 

Vega L, Sanchez-de-Toledo J, Gran F, et al. Prevention of opioid withdrawal syndrome after pediatric heart transplantation: usefulness of dexmedetomidine. Rev Esp Cardiol (Engl Ed). 2013;66(7):593–5. https://doi.org/10.1016/j.rec.2013.01.014.

Article  PubMed  Google Scholar 

Snapir A, Posti J, Kentala E et al. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology. 2006;105(5):902-10; quiz 1069-70. https://doi.org/10.1097/00000542-200611000-00010.

Bao N, Tang B. Organ-protective effects and the underlying mechanism of dexmedetomidine. Mediators Inflamm. 2020;2020:6136105. https://doi.org/10.1155/2020/6136105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuki K. The immunomodulatory mechanism of dexmedetomidine. International immunopharmacology. 2021;97: 107709. https://doi.org/10.1016/j.intimp.2021.107709.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell research. 2019;29(5):347–64. https://doi.org/10.1038/s41422-019-0164-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He Y, Yang ZY, Li JL, Li EY. Dexmedetomidine reduces the inflammation and apoptosis of doxorubicin-induced myocardial cells. Exp Mol Pathol. 2020;113:104371-. https://doi.org/10.1016/j.yexmp.2020.104371.

Chen S, Li A, Wu J, et al. Dexmedetomidine reduces myocardial ischemia-reperfusion injury in young mice through MIF/AMPK/GLUT4 axis. BMC Anesthesiol. 2022;22(1):289. https://doi.org/10.1186/s12871-022-01825-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan M, Meng XW, Ma J et al. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling. Drug Des Devel Ther. 2019;13:3137-49. https://doi.org/10.2147/dddt.S219533.

Yang FY, Zhang L, Zheng Y, Dong H. Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling. Bioengineered. 2022;13(1):1377–87. https://doi.org/10.1080/21655979.2021.2017611.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng K, Chen WR, Xia F, et al. Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling. J Cell Mol Med. 2020;24(1):850–61. https://doi.org/10.1111/jcmm.14795.

Article  CAS  PubMed  Google Scholar 

Sun T, Gong Q, Wu Y, et al. Dexmedetomidine alleviates cardiomyocyte apoptosis and cardiac dysfunction may be associated with inhibition of RhoA/ROCK pathway in mice with myocardial infarction. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(7):1569–77. https://doi.org/10.1007/s00210-021-02082-6.

Article  CAS  PubMed  Google Scholar 

Zhang C, Li XY, Luo ZZ, Wu TW, Hu H. Upregulation of LINC00982 inhibits cell proliferation and promotes cell apoptosis by regulating the activity of PI3K/AKT signaling pathway in renal cancer. Eur Rev Med Pharmacol Sci. 2019;23(4):1443-50. https://doi.org/10.26355/eurrev_201902_17101.

Wang T, Li Z, Xia S, et al. Dexmedetomidine promotes cell proliferation and inhibits cell apoptosis by regulating LINC00982 and activating the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) signaling in hypoxia/reoxygenation-induced H9c2 cells. Bioengineered. 2022;13(4):10159–67. https://doi.org/10.1080/21655979.2022.2060900.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang JH, Jin MM, Liu JT. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro. Biomed Pharmacother. 2020;127:110188. https://doi.org/10.1016/j.biopha.2020.110188.

Article  CAS  PubMed  Google Scholar 

Yu P, Zhang J, Ding Y, et al. Dexmedetomidine post-conditioning alleviates myocardial ischemia-reperfusion injury in rats by ferroptosis inhibition via SLC7A11/GPX4 axis activation. Hum Cell. 2022;35(3):836–48. https://doi.org/10.1007/s13577-022-00682-9.

Article  CAS  PubMed  Google Scholar 

Wang C, Yuan W, Hu A, et al. Dexmedetomidine alleviated sepsis-induced myocardial ferroptosis and septic heart injury. Mol Med Rep. 2020;22(1):175–84. https://doi.org/10.3892/mmr.2020.11114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Yao M, Jiang L, et al. Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis. Biomed Pharmacother. 2022;154: 113572. https://doi.org/10.1016/j.biopha.2022.113572.

Article